Conclusions on the granting of the conditional marketing authorisation and presented by the 
European Medicines Agency 
Annex IV 
32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions presented by the European Medicines Agency on: 
â€¢  Conditional marketing authorisation 
The CHMP having considered the application is of the opinion that the risk-benefit balance is 
favourable to recommend the granting of the conditional marketing authorisation as further 
explained in the European Public Assessment Report. 
33 
 
 
